HCC is a highly heterogeneous tumor, and mutations in the TP53 gene are involved in the development of intratumor heterogeneity and may contribute to treatment failure and drug resistance in many HCC patients [37,38]. This evidence concerns the gene TP53 and hepatocellular carcinoma.